0HL9 Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Affimed N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.05 |
| 52 Week High | US$8.90 |
| 52 Week Low | US$2.83 |
| Beta | 2.04 |
| 11 Month Change | -31.61% |
| 3 Month Change | -20.56% |
| 1 Year Change | -11.50% |
| 33 Year Change | -92.84% |
| 5 Year Change | n/a |
| Change since IPO | -79.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HL9 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -13.6% | -0.1% | -1.5% |
| 1Y | -11.5% | -25.8% | 5.8% |
Return vs Industry: 0HL9 exceeded the UK Biotechs industry which returned -25.8% over the past year.
Return vs Market: 0HL9 underperformed the UK Market which returned 5.8% over the past year.
Price Volatility
| 0HL9 volatility | |
|---|---|
| 0HL9 Average Weekly Movement | 28.5% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HL9's share price has been volatile over the past 3 months.
Volatility Over Time: 0HL9's weekly volatility has increased from 20% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 76 | Andreas Harstrick | www.affimed.com |
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors.
Affimed N.V. Fundamentals Summary
| 0HL9 fundamental statistics | |
|---|---|
| Market cap | US$77.51m |
| Earnings (TTM) | -US$100.56m |
| Revenue (TTM) | US$10.07m |
7.7x
P/S Ratio-0.8x
P/E RatioIs 0HL9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HL9 income statement (TTM) | |
|---|---|
| Revenue | €9.33m |
| Cost of Revenue | €0 |
| Gross Profit | €9.33m |
| Other Expenses | €102.46m |
| Earnings | -€93.13m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.12 |
| Gross Margin | 100.00% |
| Net Profit Margin | -998.61% |
| Debt/Equity Ratio | 26.6% |
How did 0HL9 perform over the long term?
See historical performance and comparison